Clinical Trial Update: The Effectiveness of a Caralluma Fimbriata Extract on Stress, Sleep and Neurotransmitters [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/Phase 3 clinical trial evaluating Caralluma fimbriata extract for stress and sleep outcomes and related neurotransmitters.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sleep Disorders
• Stress

Drugs mentioned

• Caralluma fimbriata extract

Snippet

Sponsor: RDC Clinical Pty Ltd | Conditions: Stress, Sleep | Phase 2, Phase 3 | Status: COMPLETED